accountCell Therapeutics completes enrollment in pixantrone Phase III trial; Elixir Pharmaceuticals type 2 drug mitiglinide enters final Phase III; Takeda stops development of cholesterol compound TAK-475 (lapaquistat); more R&D news, in brief...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to R&D In Brief
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account